Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropivacaine MEAC90 for Femoral Nerve Block
NCT04834440Phase 4Unknown
- Sponsor
- Healthpoint
- Start
- May 2021
- Primary completion
- Sep 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial of ropivacaine in postoperative pain, sponsored by Healthpoint. Primary endpoint: Effective analgesic femoral nerve block at 1 hour. Status: unknown.
02
Drugs
ropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04834440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04834440.